MannKind Corporation Company Profile (NASDAQ:MNKD)

About MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation logoMannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MNKD
  • CUSIP: 56400P20
  • Web:
  • Market Cap: $133.33 million
  • Outstanding Shares: 101,006,000
Average Prices:
  • 50 Day Moving Avg: $1.41
  • 200 Day Moving Avg: $1.19
  • 52 Week Range: $0.67 - $5.10
  • Trailing P/E Ratio: 0.89
  • Foreward P/E Ratio: -1.32
  • P/E Growth: -0.05
Sales & Book Value:
  • Annual Revenue: $177.77 million
  • Price / Sales: 0.75
  • Book Value: ($2.08) per share
  • Price / Book: -0.63
  • EBIDTA: $65.91 million
  • Return on Equity: -23.44%
  • Return on Assets: 54.12%
  • Debt-to-Equity Ratio: -0.39%
  • Current Ratio: 0.60%
  • Quick Ratio: 0.56%
  • Average Volume: 3.62 million shs.
  • Beta: 3.33
  • Short Ratio: 8.31
Frequently Asked Questions for MannKind Corporation (NASDAQ:MNKD)

What is MannKind Corporation's stock symbol?

MannKind Corporation trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind Corporation's earnings last quarter?

MannKind Corporation (NASDAQ:MNKD) announced its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.08. The business earned $3 million during the quarter, compared to analysts' expectations of $3.50 million. The company's revenue was up 2900.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.06) earnings per share. View MannKind Corporation's Earnings History.

Where is MannKind Corporation's stock going? Where will MannKind Corporation's stock price be in 2017?

2 brokers have issued 1-year price objectives for MannKind Corporation's shares. Their predictions range from $0.83 to $1.00. On average, they expect MannKind Corporation's stock price to reach $0.92 in the next year. View Analyst Ratings for MannKind Corporation.

Are investors shorting MannKind Corporation?

MannKind Corporation saw a decline in short interest in June. As of June 30th, there was short interest totalling 22,839,505 shares, a decline of 9.1% from the June 15th total of 25,118,910 shares. Based on an average daily volume of 2,504,553 shares, the short-interest ratio is presently 9.1 days. Approximately 37.8% of the company's shares are sold short.

Who are some of MannKind Corporation's key competitors?

Who are MannKind Corporation's key executives?

MannKind Corporation's management team includes the folowing people:

  • Kent Kresa, Chairman of the Board
  • Michael E. Castagna Pharm.D., Chief Executive Officer, Director
  • Rosabel R. Alinaya, Acting Chief Financial Officer, Senior Vice President, Chief Accounting Officer
  • Linda Adreveno, Senior Vice President - Human Resources
  • Joseph Kocinsky, Chief Technology Officer, Corporate Vice President
  • David B. Thomson Ph.D., J.D., Corporate Vice President, General Counsel, Corporate Secretary
  • Raymond W. Urbanski M.D., Ph.D., Corporate Vice President, Chief Medical Officer
  • Stuart A. Tross Ph.D., Chief People Officer
  • James Samuel Shannon M.D., Director
  • Ronald J. Consiglio, Independent Director

How do I buy MannKind Corporation stock?

Shares of MannKind Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MannKind Corporation's stock price today?

One share of MannKind Corporation stock can currently be purchased for approximately $1.32.

MarketBeat Community Rating for MannKind Corporation (NASDAQ MNKD)
Community Ranking:  2.0 out of 5 ( )
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  437
MarketBeat's community ratings are surveys of what our community members think about MannKind Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MannKind Corporation (NASDAQ:MNKD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: $0.92 (30.68% downside)

Analysts' Ratings History for MannKind Corporation (NASDAQ:MNKD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017J P Morgan Chase & CoReiterated RatingUnderweightHighView Rating Details
5/11/2017Piper Jaffray CompaniesSet Price TargetSell$1.00MediumView Rating Details
5/8/2017S&P Equity ResearchLower Price Target$1.04 -> $0.83HighView Rating Details
6/1/2016Royal Bank Of CanadaLower Price TargetUnderperform$1.00 -> $0.15N/AView Rating Details
4/28/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
4/1/2016Goldman Sachs Group, Inc. (The)Reiterated RatingSellN/AView Rating Details
1/6/2016Griffin SecuritiesUpgradeNeutral -> Buy$4.00N/AView Rating Details
11/14/2015Jefferies Group LLCReiterated RatingBuy$9.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for MannKind Corporation (NASDAQ:MNKD)
Earnings by Quarter for MannKind Corporation (NASDAQ:MNKD)
Earnings History by Quarter for MannKind Corporation (NASDAQ MNKD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.09)($0.17)$3.50 million$3.00 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.20)($0.19)$6.00 million$12.40 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.06)$0.26$2.00 million$162.35 millionViewListenView Earnings Details
8/8/2016Q2($0.06)($0.07)$0.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.06)ViewN/AView Earnings Details
3/14/2016Q4($0.05)($0.66)$0.35 millionViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.08)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.07)$0.53 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.08)$5.40 millionViewListenView Earnings Details
2/24/2015Q414($0.09)($0.09)$3.13 millionViewListenView Earnings Details
11/3/2014Q314$0.09($0.09)$66.60 millionViewListenView Earnings Details
8/11/2014Q214($0.11)($0.19)ViewListenView Earnings Details
5/12/2014Q114($0.13)($0.14)ViewListenView Earnings Details
2/18/2014Q4($0.14)($0.16)$0.43 millionViewListenView Earnings Details
11/4/2013Q313($0.14)($0.17)ViewListenView Earnings Details
8/9/2013Q2 2013($0.14)($0.16)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.15)($0.15)ViewListenView Earnings Details
2/11/2013Q4 2012($0.19)($0.23)ViewListenView Earnings Details
11/1/2012Q312($0.24)($0.22)ViewN/AView Earnings Details
8/7/2012($0.24)($0.23)ViewN/AView Earnings Details
5/9/2012($0.23)($0.27)ViewN/AView Earnings Details
2/22/2012($0.32)($0.30)ViewN/AView Earnings Details
11/3/2011($0.32)($0.31)ViewN/AView Earnings Details
8/4/2011($0.30)($0.37)ViewN/AView Earnings Details
5/9/2011($0.29)($0.34)ViewN/AView Earnings Details
2/10/2011($0.40)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MannKind Corporation (NASDAQ:MNKD)
Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-1.00 EPS


Dividend History for MannKind Corporation (NASDAQ:MNKD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for MannKind Corporation (NASDAQ:MNKD)
Insider Ownership Percentage: 1.60%
Institutional Ownership Percentage: 17.73%
Insider Trades by Quarter for MannKind Corporation (NASDAQ:MNKD)
Institutional Ownership by Quarter for MannKind Corporation (NASDAQ:MNKD)
Insider Trades by Quarter for MannKind Corporation (NASDAQ:MNKD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Matthew J PfefferCEOBuy4,540$0.54$2,451.60View SEC Filing  
1/3/2017Rosabel Realica AlinayaSVPBuy9,043$0.54$4,883.22View SEC Filing  
8/26/2016Michael CastagnaInsiderBuy17,500$0.78$13,650.00View SEC Filing  
8/24/2016Michael CastagnaInsiderBuy15,000$0.87$13,050.00View SEC Filing  
8/23/2016Michael CastagnaInsiderBuy25,000$0.94$23,500.00View SEC Filing  
8/15/2016Matthew J PfefferCEOBuy25,000$0.99$24,750.00View SEC Filing  
8/12/2016Michael CastagnaInsiderBuy25,000$1.00$25,000.00View SEC Filing  
5/17/2016Michael CastagnaInsiderBuy50,000$0.93$46,500.00View SEC Filing  
4/24/2015Hakan EdstromCEOSell73,460$4.83$354,811.80View SEC Filing  
3/27/2015Hakan EdstromCEOSell73,460$5.21$382,726.60View SEC Filing  
2/10/2015Hakan EdstromCEOSell73,460$7.75$569,315.00View SEC Filing  
2/5/2015David ThomsonVPSell80,000$7.00$560,000.00View SEC Filing  
1/5/2015Diane PalumboVPSell188,999$5.95$1,124,544.05View SEC Filing  
11/24/2014David ThomsonVPSell118,114$6.14$725,219.96View SEC Filing  
10/3/2014Juergen MartensVPSell63,800$5.48$349,624.00View SEC Filing  
8/27/2014Juergen MartensVPSell417$7.60$3,169.20View SEC Filing  
8/7/2014David ThomsonVPSell30,000$8.16$244,800.00View SEC Filing  
7/21/2014Juergen MartensVPSell26,458$9.65$255,319.70View SEC Filing  
7/15/2014Diane PalumboVPSell17,901$10.01$179,189.01View SEC Filing  
7/1/2014Matthew J PfefferCFOSell20,000$10.44$208,800.00View SEC Filing  
6/30/2014Hakan EdstromCOOBuy1,692$4.42$7,478.64View SEC Filing  
6/27/2014Juergen MartensVPSell25,417$10.53$267,641.01View SEC Filing  
6/26/2014David ThomsonVPSell30,000$10.51$315,300.00View SEC Filing  
6/20/2014Juergen MartensVPSell1,458$10.34$15,075.72View SEC Filing  
6/16/2014Diane PalumboVPSell17,902$10.59$189,582.18View SEC Filing  
6/5/2014Juergen MartensVPSell120,000$11.00$1,320,000.00View SEC Filing  
6/4/2014David ThomsonVPSell133,000$9.95$1,323,350.00View SEC Filing  
6/3/2014Diane PalumboVPSell52,957$9.50$503,091.50View SEC Filing  
5/23/2014Juergen MartensVPSell25,000$7.65$191,250.00View SEC Filing  
5/19/2014Juergen MartensVPSell76,899$7.50$576,742.50View SEC Filing  
5/15/2014Diane PalumboVPSell18,176$7.06$128,322.56View SEC Filing  
1/24/2014Juergen MartensVPSell50,000$5.56$278,000.00View SEC Filing  
12/31/2013Hakan EdstromCOOBuy1,589$4.53$7,198.17View SEC Filing  
12/20/2013Juergen MartensVPSell32,054$5.00$160,270.00View SEC Filing  
12/11/2013David ThomsonVPSell150,000$5.00$750,000.00View SEC Filing  
11/29/2013Juergen MartensVPSell48,057$5.01$240,765.57View SEC Filing  
11/15/2013Diane PalumboVPSell25,000$5.02$125,500.00View SEC Filing  
8/28/2013David ThomsonVPSell19,204$5.78$110,999.12View SEC Filing  
8/26/2013Juergen MartensVPSell20,000$5.52$110,400.00View SEC Filing  
8/1/2013Matthew J PfefferCFOSell10,000$8.00$80,000.00View SEC Filing  
7/2/2013Matthew J PfefferCFOSell10,000$7.00$70,000.00View SEC Filing  
6/30/2013Diane PalumboVPBuy1,610$1.96$3,155.60View SEC Filing  
6/30/2013Matthew J PfefferCFOBuy7,448$1.96$14,598.08View SEC Filing  
6/3/2013Diane PalumboVPSell66,849$7.50$501,367.50View SEC Filing  
5/16/2013Diane PalumboVPSell26,829$5.25$140,852.25View SEC Filing  
5/15/2013Matthew J PfefferCFOSell10,000$5.00$50,000.00View SEC Filing  
12/31/2012Matthew J PfefferCFOBuy1,056$1.95$2,059.20View SEC Filing  
12/21/2012Alfred E MannMajor ShareholderBuy40,000,000$2.59$103,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for MannKind Corporation (NASDAQ:MNKD)
Latest Headlines for MannKind Corporation (NASDAQ:MNKD)
DateHeadline logoMannKind Corporation to Hold 2017 Second Quarter Financial Results Conference Call on August 7, 2017 - GlobeNewswire (press release) - July 26 at 12:35 AM logoMannKind: Assessing The Insurance Landscape For Afrezza - Seeking Alpha - July 26 at 12:35 AM logoMannKind Corporation to Hold 2017 Second Quarter Financial Results Conference Call on August 7, 2017 - July 26 at 12:35 AM logoMannKind (MNKD) Names Steven Binder as CFO - July 18 at 11:35 PM logoSteven Binder Joins MannKind as Chief Financial Officer - July 17 at 10:20 AM logoMannKind Corporation (MNKD) Short Interest Down 9.1% in June - July 16 at 7:12 AM logoToday's Research Reports on Stocks to Watch: Mannkind Corporation and AstraZeneca - July 15 at 6:31 AM logoOptions Traders Expect Huge Moves in MannKind (MNKD) Stock - Yahoo Finance - July 14 at 6:31 AM logoOptions Traders Expect Huge Moves in MannKind (MNKD) Stock - July 14 at 6:31 AM logoPatrick McCauley Joins MannKind as Chief Commercial Officer - July 13 at 6:52 AM logoMannKind: Weekly Afrezza Scripts Leveling Off Above 300 - Seeking Alpha - July 9 at 7:20 PM logoBRIEF-Mannkind renegotiates near-term maturities with Deerfield - July 1 at 9:06 PM logoMannKind Maxes Out Its Last Credit Card - Seeking Alpha - June 30 at 1:41 AM logoMannKind Renegotiates Debt Payment To Deerfield - Seeking Alpha - June 30 at 1:41 AM logoMannKind Renegotiates Near-Term Maturities with Deerfield - June 30 at 1:41 AM logoMannKind (MNKD) Draws Remaining Funds Pursuant to Terms of Mann Group Loan Arrangement - - June 28 at 10:07 AM logoMannKind Draws Remaining Funds under Mann Group Loan Arrangement - June 28 at 10:07 AM logoMannKind: Afrezza Sales See Best Result In More Than A Year ... - Seeking Alpha - June 26 at 12:15 AM logoMannKind: Afrezza Scripts Above 300 - Can Sales Keep Climbing? - Seeking Alpha - June 20 at 7:36 PM logoA Medical Doctor's Perspective On MannKind Corp.'s Revolutionary Diabetes Mellitus Treatments - June 17 at 7:22 PM logoIs the Options Market Predicting a Spike in MannKind (MNKD) Stock? - June 16 at 7:33 PM logoMannKind Scripts Not Helping Cash Situation - Seeking Alpha - June 14 at 10:14 PM logoMannKind Co. (MNKD) Short Interest Update - June 11 at 7:26 AM logoMannKind Engages Locust Walk to Explore Strategic Options for MannKind’s Non-insulin Technosphere-based Pipeline Candidates - June 5 at 9:17 AM logoMannKind Co. (MNKD) Downgraded by ValuEngine to Hold - June 4 at 7:43 AM logoMannKind and Biomm Enter Into Distribution Agreement for Afrezza in Brazil - Nasdaq - May 31 at 6:57 PM logoMannKind and Biomm Enter Into Distribution Agreement for Afrezza in Brazil - May 31 at 6:06 PM logoMannKind Provides Update on Senior Management - GlobeNewswire (press release) - May 31 at 8:16 AM logoMannKind Corporation (MNKD) Catches Eye: Stock Jumps 7% - May 30 at 10:02 AM logoMannKind Provides Update on Senior Management - May 30 at 10:02 AM logoMannKind Co. (MNKD) Sees Large Growth in Short Interest - May 26 at 7:53 AM logoJPMorgan Chase & Co. Reaffirms Underweight Rating for MannKind Co. (MNKD) - May 22 at 10:54 AM logoReading MannKind's SEC Documents Would Help Investors Preserve Their Capital - Seeking Alpha - May 19 at 11:15 AM logoHealth Care Sector Update for 05/16/2017: MNKD,AKBA,FMS,ETRM - Nasdaq - May 18 at 8:26 AM logoMannKind Co. (MNKD) Earns "Sell" Rating from JPMorgan Chase & Co. - May 13 at 6:26 PM logoMannKind Co. (MNKD) Given a $1.00 Price Target by Piper Jaffray Companies Analysts - May 13 at 6:26 PM logoMannKind Corp.: Nothing But Losses - Seeking Alpha - May 12 at 7:12 PM logoMannKind Reports Q1 Loss - What Investors Need To Know - Seeking Alpha - May 11 at 7:05 PM logoImplied Volatility Surging for MannKind Corporation (MNKD) Stock Options - Nasdaq - May 11 at 7:05 PM logoImplied Volatility Surging for MannKind Corporation (MNKD) Stock Options - May 11 at 7:05 PM logoHere's Why MannKind Corporation Stock Is Tanking Today - May 11 at 7:05 PM logoHere's Why MannKind Corporation Stock Is Tanking Today - May 11 at 4:16 PM logoMannKind Corporation (MNKD) Stock Slammed Despite Smaller Q1 Losses - May 11 at 11:43 AM logoMannKind Q1 revenue disappoints, shares down 15% - May 11 at 11:20 AM logoMannKind's (MNKD) CEO Matthew Pfeffer on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - May 11 at 7:00 AM logoEdited Transcript of MNKD earnings conference call or presentation 10-May-17 9:00pm GMT - May 11 at 6:59 AM logoMannKind Co. (MNKD) Announces Quarterly Earnings Results, Misses Estimates By $0.29 EPS - May 10 at 11:48 PM logo10-Q: MANNKIND CORP - May 10 at 6:41 PM logoMannKind Corporation Reports 2017 First Quarter Financial Results - May 10 at 6:41 PM logoMannKind reports 1Q loss - May 10 at 6:41 PM



MannKind Corporation (MNKD) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff